ArticleAnnals of medicine2025
Immunosenescence phenotypes and prognostic significance of CD8 + CD28- T cells in AIDS-related non-Hodgkin lymphoma.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HIV associated immune aging among people living with HIV: implications for long-term antiretroviral therapy and potential HIV cure interventions in sub-Saharan Africa.Frontiers in immunology · 2026Review
- HIV infection and immunosenescence: challenges and intervention strategies.BMC medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAIDS-related non-Hodgkin lymphoma (AR-NHL), a leading malignancy among people living with HIV (PLWH), may not receive standard intensive curative therapies as the general population due to immune deficiency concerns, even in the combined antiretroviral therapy (cART) and immunochemotherapy era. Thus, a comprehensive understanding of T-cell subsets landscapes is urgently needed to grasp the complex and dynamic role of the immune system in AR-NHL patients' survival. MATERIALS AND
methodsThis longitudinal cohort study enrolled 31
resultsAR-NHL patients exhibited comparable 1-year overall survival (71.0% vs. 74.8%) and progression-free survival (60.4% vs. 64.6%) to HIV-negative NHL individuals. Baseline β2-microglobulin (β2-MG), erythrocyte sedimentation rate, and EBER positivity were higher in AR-NHL. AR-NHL revealed persistent immune senescence during immunochemotherapy, including reduced CD4+ T cells, lower CD4/CD8 ratio, decreased Tregs, naïve CD45RA+, and memory CD45RO + CD4+ T cells, alongside elevated Tregs/CD4, CD8+, CD8 + CD28+, and CD8 + CD28- T cells, highlighting the complex HIV-driven immune compromise. Multivariate analysis identified baseline circulating CD8 + CD28- T cells as an independent predictor of inferior prognosis in AR-NHL, correlated with aggressive disease markers such as elevated β2-MG, hypoproteinemia, decreased CD4/CD8 ratio, high International Prognostic Index score, and EBER positivity.
conclusionsAR-NHL patients warrant standard full-dose cancer therapy to improve prognosis despite immunocompromised and immunosenescence phenotypes. CD8 + CD28- T cells serve as an independent prognostic biomarker for AR-NHL, potentially associated with chronic immune activation and viral exposure. Our data suggest that characterizing T-cell subsets may enhance understanding of immune dynamics in AR-NHL, providing a foundation for exploring personalized approaches to infection prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.